Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy

被引：9

作者：

Liao, Shuang-Lu ^{[1
,2
,3
]}

Yu, Miao ^{[1
,2
,3
,4
]}

Zhao, Zuo-Tao ^{[1
,2
,3
]}

Maurer, Marcus ^{[5
]}

机构：

[1] Peking Univ First Hosp, Dept Dermatol & Venerol, Beijing, Peoples R China

[2] Beijing Key Lab Mol Diag Dermatoses, Beijing, Peoples R China

[3] Natl Clin Res Ctr Skin & Immune Dis, Beijing, Peoples R China

[4] Peking Univ, Sch Nursing, Beijing, Peoples R China

[5] Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Dermatol Allergol, Berlin, Germany

来源：

FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷

关键词：

omalizumab; pregnancy; chronic spontaneous urticaria; wheals; angioedema;

D O I：

10.3389/fimmu.2021.652973

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Most chronic spontaneous urticaria (CSU) patients are female, and pregnancy can aggravate the disease activity of patients, but little is known about the efficacy and safety of omalizumab in pregnant CSU patients. We report two pregnant CSU patients treated with omalizumab and review the published information on omalizumab treatment during 11 pregnancies. The outcomes reported on patients with known pregnancies showed they had normal pregnancies and healthy babies as well as complete control of their CSU. The two new cases we reported support the view that omalizumab could be an effective and safe treatment option for pregnant and breastfeeding CSU patients. Further high-quality studies need to be carried out in order to obtain more information on the long-term efficacy and safety of the use of omalizumab during pregnancy in patients with chronic urticaria, including CSU.

引用

页数：4

共 50 条

[31] Cyclosporine for the treatment of chronic spontaneous urticaria refractory to antihistamines and omalizumab: a case series
Mateu-Arrom, Laura
Gimenez-Arnau, Ana M.
Exposito-Serrano, Vicente
Bonfill-Orti, Montserrat
Serra-Baldrich, Esther
Yelamos, Oriol
Spertino, Jorge
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2025, 64 (01) : 219 - 220
[32] Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature
Passanisi, Stefano
Arasi, Stefania
Caminiti, Lucia
Crisafulli, Giuseppe
Salzano, Giuseppina
Pajno, Giovanni B.
DERMATOLOGIC THERAPY, 2020, 33 (04)
[33] A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria
Lefevre, Anna Cecilie
Deleuran, Mette
Vestergaard, Christian
ANNALS OF DERMATOLOGY, 2013, 25 (02) : 242 - 245
[34] Omalizumab in chronic spontaneous urticaria: steroid sparing effect
Gatta, Alessia
Della Valle, Loredana
Farinelli, Anila
Cavallucci, Enrico
Paganelli, Roberto
Di Gioacchino, Mario
JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 : 6 - 9
[35] Omalizumab Therapy for Chronic Spontaneous Urticaria: The Israeli Experience
Rottem, Menachem
Segal, Ramit
Kivity, Shmuel
Shamshines, Laliv
Graif, Yael
Shalit, Meir
Kessel, Aharon
Panasoff, Josef
Cohen, Shai
Toubi, Elias
Agmon-Levin, Nancy
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (08): : 487 - 490
[36] Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria
Ji, Ping
Chen, Hao
Yang, Yaqi
Yang, Lin
Wang, Yin
Liu, Guanghui
Zhu, Rongfei
CYTOKINE, 2025, 185
[37] Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria
Aude Belbezier
Isabelle Boccon-Gibod
Laurence Bouillet
European Journal of Dermatology, 2021, 31 : 86 - 87
[38] Treatment of Chronic Spontaneous Urticaria: a Focused Update in Omalizumab
Blackwell, Whitney A.
Khan, David A.
CURRENT TREATMENT OPTIONS IN ALLERGY, 2019, 6 (03) : 175 - 188
[39] Chronic Spontaneous Urticaria and omalizumab: the need for personalized treatment
Mansard, C.
Boccon-Gibod, I
Bouillet, L.
ALLERGY, 2015, 70 : 483 - 483
[40] Safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria
Maurer, M.
Rosen, K.
Hsieh, H.
Blogg, M.
Georgiou, P.
Braeutigam, M.
Saini, S.
ALLERGY, 2012, 67 : 497 - 498

← 1 2 3 4 5 →